George Washington and Minnesota universities-founded cell therapy developer Catamaran has raised cash to move two assets toward the clinic.

Catamaran Bio, a US-based cancer treatment developer founded out of University of Minnesota and George Washington University (GWU), launched yesterday with $42m of series A funding co-led by Sofinnova Partners and Lightstone Ventures. Takeda Ventures, a strategic investment arm of pharmaceutical firm Takeda, also took part in the round, as did SV Health Investors and Astellas Venture Management. Founded in September 2019, Catamaran Bio is developing cell therapies for a broad range of cancers, including solid tumours. The spinout hopes to deliver off-the-shelf drugs, as opposed to some cell therapy treatments that require samples extracted from the patient. Catamaran Bio will use the funding to progress two lead programs into the clinic and for upgrades to its underlying cell engineering technology. SV Health Investors participated in the series A round as Catamaran Bio’s founding investor, but further details could not be confirmed. Kevin Pojasek and Tim Harris, venture partners at SV Health, are among Catamaran’s co-founders, as are Prof Catherine Bollard of GWU and Branden Moriarity, an assistant professor at University of Minnesota.

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?